Biocytogen’s antibody Business Development & Licensing team is excited to attend the upcoming Immuno-Oncology Summit Europe 2024 conference, set to take place in London, UK, from April 23-25, 2024! During the event, our team will present a poster, titled “Fully human conditional agonist 4-1BB x CD40 bispecific antibody exhibits potent in vitro and in vivo efficacy”. Our novel 4-1BB x CD40 bispecific antibody (BCG021) significantly enhanced the in vivo anti-tumor efficacy of the anti-PD-1 monoclonal antibody. Furthermore, preclinical studies in mouse models indicated a favorable safety profile for BCG021.

Bispecific antibodies offer novel therapeutic mechanisms, distinct from both monotherapies and combination therapies. They offer conditional activation or precise targeting of the tumor microenvironment to mitigate systemic toxicity. Additionally, bispecific antibodies provide dual blockade abilities, effectively addressing drug resistance concerns.

To facilitate the development of bispecific antibodies, Biocytogen has developed RenLite^® mice capable of generating fully human common light chain antibodies, which serve as building blocks for constructing Y-shaped bispecific antibodies. Using this strategy, we have developed CTLA-4 x OX40 bsAb for oncology, OX40 biparatopic bsAb for autoimmune diseases, and other bispecific antibodies.

We look forward to exploring partnership opportunities with you, either for our antibody-based assets, or our antibody discovery platforms! For questions, please contact BD-Licensing@biocytogen.com.